0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Significance of Drug Interactions With Rifampin in Pneumocystis carinii Pneumonia Prophylaxis

Ulrich P. Jorde, MD; Harold W. Horowitz, MD; Gary P. Wormser, MD
Arch Intern Med. 1992;152(11):2348. doi:10.1001/archinte.1992.00400230140031.
Text Size: A A A
Published online

To the Editor.—  In a recent issue of the ARCHIVES,1 an update on drug interactions with rifampin was presented. The authors mention the possible clinical importance of such interactions in the treatment of Pneumocystis carinii pneumonia (PCP) with dapsone.We share this concern and have recently cautioned about potential problems with the combination of dapsone and rifampin treatment in prophylaxis of PCP.2 Dosage regimens used in prophylaxis are often lower than those used for treatment purposes, and pharmacokinetic interactions may, thus, have an even greater impact. Intermittent dosage regimens, a common practice in PCP prophylaxis with dapsone therapy, may be particularly problematic. Borcherding et al1 indicate that interactions of rifampin with dapsone in the treatment of leprosy have been investigated and do not appear to be clinically important. This may be explained by the exquisite sensitivity of Mycobacterium leprae to dapsone (2.5 to 10 μg/L).The minimal

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();